Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Gilead Sciences has set the price of its investigational Covid-19 drug remdesivir at $390 per vial for the US and governments of other developed countries.
Current treatment patterns reveal that most patients may require a five-day treatment course, which involves six vials of remdesivir, pricing the course at $2,340 per patient.
The price of the drug has been under debate since it secured emergency use authorisation from the US Food and Drug Administration (FDA) in May to treat Covid-19 patients.
In an open letter, Gilead chairman and CEO Daniel O’Day said: “Part of the intent behind our decision was to remove the need for.